Cointime

Agendia

company

About

Agendia provides molecular diagnostics and personalized treatment plans for cancer patients.

  • 101 - 250

Highlights

Total Funding Amount
$65M
Funding Rounds
1
Investors
2

Details

Last Funding Type
Private Equity（PE）
Last Funding Money Raised
$65M
Industries
Biotechnology,Genetics,Health Care,Health Diagnostics,Life Science,Medical
Founded date
Jan 1, 2003
Number Of Employee
101 - 250
Operating Status
Active

Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$65M
Agendia has raised a total of $65M in funding over 2 rounds. Their latest funding was raised on May 31, 2012 from a Private Equity（PE） round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 31, 2012 Private Equity（PE） $65M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Agendia is funded by 2 investors. Breedinvest and ING Corporate Investments are the most recent investors.
Investor Name Lead Investor Funding Round
Breedinvest — Private Equity（PE）
ING Corporate Investments — Private Equity（PE）
Cointime
Chủ Đề
Công Ty